Charu Mehta currently serves as an Accounting Officer at CEPI since September 2023 and has been a Business Development Manager at Basant since September 2022, focusing on business growth and client acquisition. Previously, Charu held positions such as Administrative Assistant at Ajoy Prints, where responsibilities included financial statement preparation and tax matters, and Accounting Assistant at M.B. Advani & Co., focusing on tax returns. Additional experience includes a Management Trainee role at Uma Polymers Limited, assisting with corporate affairs, and an Articled Assistant position at M/s R.P Mundra & Company, collaborating on audits. Charu's educational background includes a Company Secretary degree from The Institute of Company Secretaries of India and a Bachelor's Degree in Accounting Honors from Jai Narain Vyas University.
This person is not in any teams
CEPI (Coalition for Epidemic Preparedness Innovations)
2 followers
CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos in 2017, to develop vaccines against future epidemics. Prior to COVID-19, CEPI’s work focused on developing vaccines against the Ebola Virus Disease, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever virus and Chikungunya virus. It has over 20 vaccine candidates against these pathogens in development. CEPI has also invested in new platform technologies for rapid vaccine development against unknown pathogens (Disease X). During the COVID-19 pandemic, CEPI initiated multiple programmes to develop vaccines against SARS-CoV-2 and its variants with a focus on speed, scale, and access. These programmes leverage the rapid response platforms developed by CEPI’s partners prior to the emergence of COVID-19, as well as new collaborations. The aim is to advance clinical development of a diverse portfolio of safe and effective COVID-19 candidates and to enable fair allocation of these vaccines worldwide through COVAX. CEPI’s 5-year plan lays out a $3.5 billion roadmap to compress vaccine development timelines to 100 days, develop a broadly protective vaccine against COVID-19 and other Betacoronaviruses, and create a “library” of vaccine candidates for use against known and unknown pathogens. The plan is available at www.endpandemics.cepi.net